The power of AI as a gamechanger for omnichannel promotional content is becoming well known, especially as large language models (LLMs) evolve in sophistication. Advances in model architecture, improved training techniques, and better handling of nuance, ambiguity, bias, and context make AI increasingly suitable for a range of biopharma functions, including medical affairs. These developments are enabling more efficient, personalized, and consistent delivery of scientific information to healthcare professionals (HCPs) across various channels.
LLMs are transforming how medical affairs teams communicate scientific and medical information, both online and offline. Because HCPs have unique educational backgrounds, therapeutic expertise, and preferences for communication formats, delivering the right information through the right channel at the right time is critical. AI-powered omnichannel engagement allows medical affairs teams to tailor content based on an HCP’s needs, whether it’s detailed clinical data for a specialist or high-level updates for a general practitioner.
However, simply segmenting audiences and creating modular content, as has been done traditionally, no longer guarantees optimal engagement. Today’s medical landscape demands more. LLMs offer the ability to deliver consistent, timely, and evidence-based communications while adapting to HCPs’ evolving preferences. This level of personalization and efficiency is crucial, especially when dealing with multiple content formats such as peer-reviewed articles, online videos, and symposia presentations. While MSLs and CRM tools continue to play a key role, LLMs enable a level of scale and precision previously unattainable. But is it perfect? Not quite.
Challenges and Solutions in Deploying LLMs for Medical Affairs
1. Regulatory Compliance and Data Privacy
Challenge: Medical affairs teams must ensure that LLMs comply with stringent regulatory standards from bodies like the FDA, EMA, and other regulators. These include managing off-label discussions, ensuring proper adverse event reporting, and adhering to promotional compliance regulations. Patient data privacy is also a concern, as laws such as HIPAA and GDPR dictate how data is handled. The challenge is ensuring LLMs respect these privacy standards while maintaining accuracy.
Solution: To mitigate risks, LLMs must be rigorously trained to avoid off-label discussions, ensure accurate adverse event reporting, and comply with regulatory guidelines. Regular audits of AI outputs will verify adherence to these standards, while data anonymization and strict management protocols can safeguard patient privacy. Compliance teams should collaborate with AI experts to ensure LLM outputs align with regulations like HIPAA and GDPR, providing peace of mind in sensitive applications.
2. Content Accuracy and Consistency
Challenge: HCPs rely on medical affairs teams for accurate, evidence-based information. Inconsistent or inaccurate information could jeopardize patient safety and the company’s reputation. LLMs must consistently generate medically accurate responses across all communication channels—email, chatbots, or CRM—while also tailoring content to different audiences. Ensuring up-to-date and consistent information across various platforms is essential but challenging.
Solution: Establish strong validation processes for LLM-generated content including regular updates to sources including the latest scientific literature. Medical experts should review AI outputs to maintain accuracy. Implement version control to track changes in guidelines, ensuring consistency across channels and audiences, from HCPs to internal stakeholders. By maintaining rigorous oversight, LLMs can produce reliable, accurate content across all platforms, enhancing trust in AI-powered communication.
3. Integration and Scalability
Challenge: Integrating LLMs into existing systems such as CRMs, content management systems, and analytics platforms can be technically complex. Seamless API integration and workflow automation are necessary for smooth operation. Additionally, scaling LLMs across different regions, languages, and therapeutic areas while maintaining high quality and regulatory compliance presents another layer of difficulty, particularly in global markets with varying local regulations.
Solution: The AI space is evolving rapidly so partner with vendors who specialize in LLM integration to address technical challenges like data interoperability and workflow automation. Experienced AI providers are marrying data science and knowledge graphs in semantic graph platforms to help organizations overcome scalability challenges. These advances can accelerate core data science processes like data preparation, feature engineering, and the uptake of machine learning to greatly increase the success of AI projects. These external experts can also guide internal teams in API connectivity and system integration. The final piece is aligning with compliance teams, data scientists, medical professionals, and IT specialists across your organization to ensure that LLMs maintain consistency, quality, and compliance, even as they adapt to different languages, markets, and therapeutic areas.
The Long-Term Vision
The adoption of AI in medical affairs is already underway, but its full integration and maturity across the industry will likely span a longer timeline than just the next 12-18 months. While certain applications, such as chatbots for medical queries and automated content generation, are becoming more common, more complex uses like real-time multi-channel engagement and advanced regulatory-compliant communications will take longer.
Given the sensitive and highly regulated nature of the healthcare industry, we can estimate a 2-5 year period for widespread adoption. This timeframe accounts for ongoing improvements in AI technologies, compliance processes, and changes in regulatory standards. The next 12-18 months will likely see more pilot programs, vendor collaborations, and the gradual integration of AI into select medical affairs activities. However, achieving industry-wide confidence in AI-driven solutions and fully addressing challenges like data privacy, content accuracy, and regulatory compliance may extend this adoption timeline.
About Bluebuck Ventures
Bluebuck Ventures (www.bluebuckventures.com) is a consulting firm specializing in accelerating growth for life science and pharma technology companies. With deep expertise in commercial strategy, market entry, and omnichannel engagement, Bluebuck partners with clients to address critical challenges in compliance, data privacy, and integration within highly regulated industries. Leveraging years of experience in the pharmaceutical sector, Bluebuck Ventures provides tailored solutions, helping companies to navigate complex landscapes, optimize go-to-market strategies, and achieve sustainable success in their markets.
Sources
Nature.com – How AI is being used to accelerate clinical trials
https://www.nature.com/articles/d41586-024-00753-x
McKinsey & Company – AI in Life Sciences:
https://www.mckinsey.com/industries/life-sciences/our-insights/how-artificial-intelligence-can-improve-pharma-manufacturing
About the author:
Jeremy Schwarz
Jeremy Schwarz is a dynamic commercial leader and co-founder of Bluebuck Ventures LLC, known for his expertise in life sciences technology and operations. He has a strong track record of guiding companies through complex growth challenges, architecting commercial organizations, and building effective teams. At Veeva Systems, Jeremy worked closely with commercial and medical teams, enhancing engagement strategies and leading efforts across North American Enterprise and global accounts. His experience extends to clinical operations technology and real-world data, where he has helped streamline processes and deliver scalable solutions. Now, at Bluebuck Ventures, Jeremy partners with clients to fill critical gaps and accelerate their path from innovation to market success.
Malia Lewin
Malia Lewin is a seasoned strategist and co-founder of Bluebuck Ventures LLC, with over two decades of expertise in commercial strategy and leadership within the life sciences sector. Her experience includes developing and executing go-to-market strategies, leading cross-functional teams, building strategic partnerships, and guiding companies through key growth phases. As a Market Owner at Veeva Systems and lead strategist at QBDVision, Teckro and Lexitas, she shaped market entry strategies and collaborated with commercial and medical teams in biopharma to drive product adoption. Malia has also served on boards, managed investor relations, and contributed to fundraising efforts. At Bluebuck Ventures, she uses her expertise to craft tailored commercial strategies, helping clients achieve their full potential and drive meaningful change in the healthcare industry.
Have an opinion on this article? Send a message to the editor.